



Fund Details

Investment Objective

The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes' objectives will be achieved.

Fund Manager

Mr. Dhaval Shah & Mr. Dhaval Joshi

Date of Allotment

July 11, 2019

Benchmark

S&P BSE Healthcare TRI

Managing Fund Since

July 11, 2019 & November 21, 2022

Experience in Managing the Fund

3.9 Years & 0.5 Years

SIP

Monthly: Minimum ₹ 500/-

Fund Category

Thematic (Equity)

Investment Style

Large Cap	High	Low	Low
Mid Cap	High	Low	Low
Small Cap	High	Low	Low
	Growth	Value	Blend



Load Structure (as % of NAV) (Incl. for SIP)

Entry Load	Nil
Exit Load	For redemption/switchout of units on or before 30 days from the date of allotment:1.00% of applicable NAV. For redemption/switch-out of units after 30 days from the date of allotment: Nil

AUM

Monthly Average AUM	₹ 451.12	Crores
AUM as on last day	₹ 454.83	Crores

Total Expense Ratio (TER)

Regular	2.45%
Direct	1.10%
Including additional expenses and goods and service tax on management fees.	

Other Parameters

Standard Deviation	14.81%
Sharpe Ratio	0.38
Beta	0.90
Portfolio Turnover	0.36

Note: Standard Deviation, Sharpe Ratio & Beta are calculated on Annualised basis using 3 years history of monthly returns. Risk Free Rate assumed to be 6.4% (FBIL Overnight MIBOR as on 31 May 2023) for calculating Sharpe Ratio

Application Amount for fresh subscription

₹ 1,000 (plus in multiples of ₹ 1)

Min. Addl. Investment

₹ 1,000 (plus in multiples of ₹ 1)

PORTFOLIO

Issuer	% to Net Assets	Rating
Pharmaceuticals & Biotechnology	77.07%	
Sun Pharmaceutical Industries Limited	14.18%	
Lupin Limited	5.93%	
Torrent Pharmaceuticals Limited	5.42%	
Aurobindo Pharma Limited	4.85%	
Dr. Reddys Laboratories Limited	4.78%	
Cipla Limited	4.26%	
Zydus Lifesciences Limited	3.84%	
Alkem Laboratories Limited	3.59%	
Biocon Limited	3.22%	
Strides Pharma Science Limited	3.15%	
Indoco Remedies Limited	2.86%	
J.B. Chemicals & Pharmaceuticals Limited	2.84%	
Sanofi India Limited	2.50%	
Abbott India Limited	2.48%	
Ajanta Pharmaceuticals Limited	2.06%	
Eris Lifesciences Limited	2.00%	
Natco Pharma Limited	1.95%	

Issuer	% to Net Assets	Rating
Mankind Pharma Ltd	1.94%	
ALEMBIC PHARMACEUTICALS LIMITED	1.94%	
Gland Pharma Limited	1.88%	
Granules India Limited	1.41%	
Healthcare Services	17.15%	
Apollo Hospitals Enterprise Limited	8.33%	
Fortis Healthcare Limited	4.88%	
Global Health Ltd/India	1.54%	
Vijaya Diagnostic Centre Limited	1.27%	
Syngene International Limited	1.13%	
Retailing	1.85%	
Medplus Health Services Limited	1.85%	
Chemicals & Petrochemicals	1.49%	
Vinati Organics Limited	1.49%	
Food Products	0.94%	
Zydus Wellness Limited	0.94%	
Cash & Current Assets	1.50%	
Total Net Assets	100.00%	

Investment Performance

NAV as on May 31, 2023: ₹ 17.4300

Inception - July 11, 2019	Since Inception	5 Years	3 Years	1 Year
Aditya Birla Sun Life Pharma & Healthcare Fund	15.34%	NA	12.03%	4.43%
Value of Std Investment of ₹ 10,000	17430	NA	14068	10443
Benchmark - S&P BSE Healthcare TRI	18.10%	NA	15.49%	6.17%
Value of Std Investment of ₹ 10,000	19112	NA	15414	10617
Additional Benchmark - Nifty 50 TRI	14.38%	NA	26.02%	12.94%
Value of Std Investment of ₹ 10,000	16874	NA	20037	11294

Past performance may or may not be sustained in future. The above performance is of Regular Plan - Growth Option. Kindly note that different plans have different expense structure. Load and Taxes are not considered for computation of returns. When scheme/additional benchmark returns are not available, they have not been shown. Total Schemes Co-Managed by Fund Managers is 1. Total Schemes managed by Mr. Dhaval Shah is 6. Total Schemes managed by Mr. Dhaval Joshi is 47. Refer annexure on page no. 169-170 to know more on performance of schemes managed by Fund Managers.

Note: The exit load (if any) rate levied at the time of redemption/switch-out of units will be the rate prevailing at the time of allotment of the corresponding units. Customers may request for a separate Exit Load Applicability Report by calling our toll free numbers 1800-270-7000 or from any of our Investor Service Centers.

NAV of Plans / Options (₹)

	Regular Plan	Direct Plan
Growth	17.4300	18.5900
IDCW ² :	13.9400	14.8800

²Income Distribution cum capital withdrawal



SIP Performance - Regular Plan - Growth (assuming SIP of ₹ 10000 per month)

Particulars	Since Inception	5 years	3 years	1 Year
Total Amount Invested (₹)	470000	NA	360000	120000
Market Value of amount Invested	557052	NA	375335	123451
Scheme Returns (CAGR)	8.65%	NA	2.73%	5.40%
S&P BSE Healthcare TRI# (CAGR)	11.60%	NA	4.79%	8.18%
Nifty 50 TRI## (CAGR)	16.15%	NA	14.70%	12.89%

Date of First Installment: August 01, 2019 & Scheme Inception Date: July 11, 2019. Past Performance may or may not be sustained in future.

Scheme Benchmark, ## Additional Benchmark

For SIP calculations above, the data assumes the investment of ₹ 10000/- on 1st day of every month or the subsequent working day. Load & Taxes are not considered for computation of returns. Performance for IDCW option would assume reinvestment of tax free IDCW declared at the then prevailing NAV. CAGR returns are computed after accounting for the cash flow by using XIRR method (investment internal rate of return). Where Benchmark returns are not available, they have not been shown. **Past performance may or may not be sustained in future.** Returns greater than 1 year period are compounded annualized. IDCW are assumed to be reinvested and bonus is adjusted. Load is not taken into consideration. For SIP returns, monthly investment of equal amounts invested on the 1st day of every month has been considered.